Epoetin alfa biosimilar - Reliance Life Sciences

Drug Profile

Epoetin alfa biosimilar - Reliance Life Sciences

Alternative Names: Epostim; ReliPoietin

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator GeneMedix Plc
  • Developer Reliance Life Sciences; Stragen Pharma SA
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 19 May 2015 No recent reports of development identified - Phase-III for Anaemia (Chemotherapy-induced) in European Union (Parenteral)
  • 19 May 2015 No recent reports of development identified - Phase-III for Anaemia in European Union (Parenteral)
  • 15 Mar 2011 Phase-III clinical trials in Anaemia (chemotherapy induced) in European Union (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top